Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Merck KGaA
Special Reports
The top 10 drugs losing US exclusivity in 2026
While megablockbusters naturally command significant attention, Fierce takes a chance each year to look at older medicines nearing their tumble over the patent cliff.
Eric Sagonowsky
,
Fraiser Kansteiner
,
Kevin Dunleavy
,
Zoey Becker
Mar 16, 2026 3:00am
Lilly, Pfizer-Sciwind, Astellas—Fierce Pharma Asia
Mar 13, 2026 8:05am
Merck KGaA expects Mavenclad generics to deal serious blow in US
Mar 5, 2026 11:30am
Ireland's drug production hub status intact amid US trade tumult
Mar 3, 2026 4:27pm
Sanofi ousts Paul Hudson for Merck KGaA chief after 'bumpy ride'
Feb 12, 2026 4:26am
Merck KGaA is turning out the lights at an Irish API plant
Oct 22, 2025 3:00pm